nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—ABCB1—Methylprednisolone—ankylosing spondylitis	0.107	0.123	CbGbCtD
Levomilnacipran—CYP2C19—Prednisone—ankylosing spondylitis	0.0807	0.0924	CbGbCtD
Levomilnacipran—ABCB1—Betamethasone—ankylosing spondylitis	0.0699	0.08	CbGbCtD
Levomilnacipran—ABCB1—Prednisolone—ankylosing spondylitis	0.069	0.0789	CbGbCtD
Levomilnacipran—ABCB1—Prednisone—ankylosing spondylitis	0.0651	0.0745	CbGbCtD
Levomilnacipran—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0644	0.0737	CbGbCtD
Levomilnacipran—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0601	0.0687	CbGbCtD
Levomilnacipran—CYP2C19—Dexamethasone—ankylosing spondylitis	0.0504	0.0577	CbGbCtD
Levomilnacipran—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0488	0.0558	CbGbCtD
Levomilnacipran—CYP3A4—Betamethasone—ankylosing spondylitis	0.0419	0.0479	CbGbCtD
Levomilnacipran—CYP3A4—Prednisolone—ankylosing spondylitis	0.0413	0.0473	CbGbCtD
Levomilnacipran—ABCB1—Dexamethasone—ankylosing spondylitis	0.0407	0.0465	CbGbCtD
Levomilnacipran—CYP3A4—Prednisone—ankylosing spondylitis	0.039	0.0446	CbGbCtD
Levomilnacipran—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0383	0.0438	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—ankylosing spondylitis	0.0327	0.0374	CbGbCtD
Levomilnacipran—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0244	0.0279	CbGbCtD
Levomilnacipran—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.000527	0.00418	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000524	0.00416	CcSEcCtD
Levomilnacipran—Neutropenia—Prednisone—ankylosing spondylitis	0.000522	0.00414	CcSEcCtD
Levomilnacipran—Irritability—Methotrexate—ankylosing spondylitis	0.000515	0.00409	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Prednisone—ankylosing spondylitis	0.000514	0.00408	CcSEcCtD
Levomilnacipran—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000512	0.00406	CcSEcCtD
Levomilnacipran—Hallucination—Betamethasone—ankylosing spondylitis	0.000511	0.00405	CcSEcCtD
Levomilnacipran—Hallucination—Dexamethasone—ankylosing spondylitis	0.000511	0.00405	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000509	0.00404	CcSEcCtD
Levomilnacipran—Weight decreased—Prednisone—ankylosing spondylitis	0.000505	0.00401	CcSEcCtD
Levomilnacipran—Vision blurred—Prednisolone—ankylosing spondylitis	0.000505	0.004	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Methotrexate—ankylosing spondylitis	0.000498	0.00396	CcSEcCtD
Levomilnacipran—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000494	0.00392	CcSEcCtD
Levomilnacipran—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000491	0.0039	CcSEcCtD
Levomilnacipran—Breast disorder—Methotrexate—ankylosing spondylitis	0.000488	0.00387	CcSEcCtD
Levomilnacipran—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000482	0.00383	CcSEcCtD
Levomilnacipran—Syncope—Prednisolone—ankylosing spondylitis	0.00048	0.00381	CcSEcCtD
Levomilnacipran—Eye disorder—Dexamethasone—ankylosing spondylitis	0.00048	0.00381	CcSEcCtD
Levomilnacipran—Eye disorder—Betamethasone—ankylosing spondylitis	0.00048	0.00381	CcSEcCtD
Levomilnacipran—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.000471	0.00373	CcSEcCtD
Levomilnacipran—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000466	0.00369	CcSEcCtD
Levomilnacipran—Angiopathy—Betamethasone—ankylosing spondylitis	0.000466	0.00369	CcSEcCtD
Levomilnacipran—Convulsion—Prednisolone—ankylosing spondylitis	0.000464	0.00368	CcSEcCtD
Levomilnacipran—Hypertension—Prednisolone—ankylosing spondylitis	0.000462	0.00367	CcSEcCtD
Levomilnacipran—Hallucination—Prednisone—ankylosing spondylitis	0.000445	0.00353	CcSEcCtD
Levomilnacipran—Syncope—Triamcinolone—ankylosing spondylitis	0.000441	0.0035	CcSEcCtD
Levomilnacipran—Syncope—Methylprednisolone—ankylosing spondylitis	0.00044	0.0035	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000439	0.00348	CcSEcCtD
Levomilnacipran—Dysuria—Methotrexate—ankylosing spondylitis	0.000436	0.00346	CcSEcCtD
Levomilnacipran—Neutropenia—Methotrexate—ankylosing spondylitis	0.000436	0.00346	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000434	0.00344	CcSEcCtD
Levomilnacipran—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000433	0.00343	CcSEcCtD
Levomilnacipran—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000432	0.00343	CcSEcCtD
Levomilnacipran—Shock—Prednisolone—ankylosing spondylitis	0.00043	0.00341	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Methotrexate—ankylosing spondylitis	0.00043	0.00341	CcSEcCtD
Levomilnacipran—Convulsion—Triamcinolone—ankylosing spondylitis	0.000427	0.00338	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisolone—ankylosing spondylitis	0.000426	0.00338	CcSEcCtD
Levomilnacipran—Convulsion—Methylprednisolone—ankylosing spondylitis	0.000426	0.00338	CcSEcCtD
Levomilnacipran—Hypertension—Triamcinolone—ankylosing spondylitis	0.000425	0.00337	CcSEcCtD
Levomilnacipran—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000424	0.00337	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000422	0.00335	CcSEcCtD
Levomilnacipran—Eye disorder—Prednisone—ankylosing spondylitis	0.000418	0.00331	CcSEcCtD
Levomilnacipran—Anxiety—Methylprednisolone—ankylosing spondylitis	0.000417	0.00331	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000415	0.0033	CcSEcCtD
Levomilnacipran—Flushing—Prednisone—ankylosing spondylitis	0.000415	0.00329	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000412	0.00327	CcSEcCtD
Levomilnacipran—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00041	0.00325	CcSEcCtD
Levomilnacipran—Angiopathy—Prednisone—ankylosing spondylitis	0.000405	0.00322	CcSEcCtD
Levomilnacipran—Syncope—Dexamethasone—ankylosing spondylitis	0.000401	0.00318	CcSEcCtD
Levomilnacipran—Syncope—Betamethasone—ankylosing spondylitis	0.000401	0.00318	CcSEcCtD
Levomilnacipran—Infection—Triamcinolone—ankylosing spondylitis	0.000399	0.00317	CcSEcCtD
Levomilnacipran—Infection—Methylprednisolone—ankylosing spondylitis	0.000398	0.00316	CcSEcCtD
Levomilnacipran—Haematuria—Methotrexate—ankylosing spondylitis	0.000397	0.00315	CcSEcCtD
Levomilnacipran—Shock—Triamcinolone—ankylosing spondylitis	0.000395	0.00314	CcSEcCtD
Levomilnacipran—Insomnia—Prednisolone—ankylosing spondylitis	0.000395	0.00314	CcSEcCtD
Levomilnacipran—Shock—Methylprednisolone—ankylosing spondylitis	0.000394	0.00313	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000393	0.00312	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000393	0.00312	CcSEcCtD
Levomilnacipran—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000393	0.00312	CcSEcCtD
Levomilnacipran—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000393	0.00312	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000392	0.00311	CcSEcCtD
Levomilnacipran—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000392	0.00311	CcSEcCtD
Levomilnacipran—Mental disorder—Prednisone—ankylosing spondylitis	0.000392	0.00311	CcSEcCtD
Levomilnacipran—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000391	0.0031	CcSEcCtD
Levomilnacipran—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000389	0.00309	CcSEcCtD
Levomilnacipran—Malnutrition—Prednisone—ankylosing spondylitis	0.000389	0.00309	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000388	0.00308	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000388	0.00308	CcSEcCtD
Levomilnacipran—Convulsion—Betamethasone—ankylosing spondylitis	0.000387	0.00307	CcSEcCtD
Levomilnacipran—Convulsion—Dexamethasone—ankylosing spondylitis	0.000387	0.00307	CcSEcCtD
Levomilnacipran—Hypertension—Dexamethasone—ankylosing spondylitis	0.000386	0.00306	CcSEcCtD
Levomilnacipran—Hypertension—Betamethasone—ankylosing spondylitis	0.000386	0.00306	CcSEcCtD
Levomilnacipran—Anxiety—Betamethasone—ankylosing spondylitis	0.000379	0.00301	CcSEcCtD
Levomilnacipran—Anxiety—Dexamethasone—ankylosing spondylitis	0.000379	0.00301	CcSEcCtD
Levomilnacipran—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000375	0.00297	CcSEcCtD
Levomilnacipran—Hepatitis—Methotrexate—ankylosing spondylitis	0.000373	0.00296	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000369	0.00293	CcSEcCtD
Levomilnacipran—Vision blurred—Prednisone—ankylosing spondylitis	0.000367	0.00291	CcSEcCtD
Levomilnacipran—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000366	0.00291	CcSEcCtD
Levomilnacipran—Insomnia—Triamcinolone—ankylosing spondylitis	0.000363	0.00288	CcSEcCtD
Levomilnacipran—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000363	0.00288	CcSEcCtD
Levomilnacipran—Infection—Dexamethasone—ankylosing spondylitis	0.000362	0.00287	CcSEcCtD
Levomilnacipran—Infection—Betamethasone—ankylosing spondylitis	0.000362	0.00287	CcSEcCtD
Levomilnacipran—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000361	0.00286	CcSEcCtD
Levomilnacipran—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.00036	0.00286	CcSEcCtD
Levomilnacipran—Shock—Dexamethasone—ankylosing spondylitis	0.000359	0.00285	CcSEcCtD
Levomilnacipran—Shock—Betamethasone—ankylosing spondylitis	0.000359	0.00285	CcSEcCtD
Levomilnacipran—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000358	0.00284	CcSEcCtD
Levomilnacipran—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000358	0.00284	CcSEcCtD
Levomilnacipran—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000358	0.00284	CcSEcCtD
Levomilnacipran—Agitation—Prednisone—ankylosing spondylitis	0.000357	0.00284	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000357	0.00283	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000357	0.00283	CcSEcCtD
Levomilnacipran—Tachycardia—Betamethasone—ankylosing spondylitis	0.000356	0.00282	CcSEcCtD
Levomilnacipran—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000356	0.00282	CcSEcCtD
Levomilnacipran—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000354	0.00281	CcSEcCtD
Levomilnacipran—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000353	0.0028	CcSEcCtD
Levomilnacipran—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000353	0.0028	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000352	0.0028	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000352	0.0028	CcSEcCtD
Levomilnacipran—Eye disorder—Methotrexate—ankylosing spondylitis	0.000349	0.00277	CcSEcCtD
Levomilnacipran—Syncope—Prednisone—ankylosing spondylitis	0.000349	0.00277	CcSEcCtD
Levomilnacipran—Anorexia—Betamethasone—ankylosing spondylitis	0.000348	0.00276	CcSEcCtD
Levomilnacipran—Anorexia—Dexamethasone—ankylosing spondylitis	0.000348	0.00276	CcSEcCtD
Levomilnacipran—Urticaria—Prednisolone—ankylosing spondylitis	0.000347	0.00275	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000347	0.00275	CcSEcCtD
Levomilnacipran—Fatigue—Triamcinolone—ankylosing spondylitis	0.000346	0.00275	CcSEcCtD
Levomilnacipran—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000346	0.00274	CcSEcCtD
Levomilnacipran—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000342	0.00271	CcSEcCtD
Levomilnacipran—Hypotension—Dexamethasone—ankylosing spondylitis	0.000341	0.0027	CcSEcCtD
Levomilnacipran—Hypotension—Betamethasone—ankylosing spondylitis	0.000341	0.0027	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—ankylosing spondylitis	0.000339	0.00269	CcSEcCtD
Levomilnacipran—Convulsion—Prednisone—ankylosing spondylitis	0.000337	0.00267	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000337	0.00267	CcSEcCtD
Levomilnacipran—Hypertension—Prednisone—ankylosing spondylitis	0.000336	0.00267	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—ankylosing spondylitis	0.000335	0.00266	CcSEcCtD
Levomilnacipran—Anxiety—Prednisone—ankylosing spondylitis	0.00033	0.00262	CcSEcCtD
Levomilnacipran—Insomnia—Betamethasone—ankylosing spondylitis	0.00033	0.00262	CcSEcCtD
Levomilnacipran—Insomnia—Dexamethasone—ankylosing spondylitis	0.00033	0.00262	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000329	0.00261	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000328	0.0026	CcSEcCtD
Levomilnacipran—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000327	0.0026	CcSEcCtD
Levomilnacipran—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000327	0.0026	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—ankylosing spondylitis	0.000327	0.0026	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—ankylosing spondylitis	0.000325	0.00258	CcSEcCtD
Levomilnacipran—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000322	0.00255	CcSEcCtD
Levomilnacipran—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000321	0.00255	CcSEcCtD
Levomilnacipran—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000321	0.00255	CcSEcCtD
Levomilnacipran—Urticaria—Triamcinolone—ankylosing spondylitis	0.000319	0.00253	CcSEcCtD
Levomilnacipran—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000318	0.00253	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000318	0.00253	CcSEcCtD
Levomilnacipran—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000318	0.00252	CcSEcCtD
Levomilnacipran—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000317	0.00251	CcSEcCtD
Levomilnacipran—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000317	0.00251	CcSEcCtD
Levomilnacipran—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000317	0.00251	CcSEcCtD
Levomilnacipran—Infection—Prednisone—ankylosing spondylitis	0.000315	0.0025	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000315	0.0025	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000315	0.0025	CcSEcCtD
Levomilnacipran—Fatigue—Dexamethasone—ankylosing spondylitis	0.000314	0.00249	CcSEcCtD
Levomilnacipran—Fatigue—Betamethasone—ankylosing spondylitis	0.000314	0.00249	CcSEcCtD
Levomilnacipran—Shock—Prednisone—ankylosing spondylitis	0.000312	0.00248	CcSEcCtD
Levomilnacipran—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000311	0.00247	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisone—ankylosing spondylitis	0.00031	0.00246	CcSEcCtD
Levomilnacipran—Skin disorder—Prednisone—ankylosing spondylitis	0.000308	0.00245	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000307	0.00244	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—ankylosing spondylitis	0.000306	0.00243	CcSEcCtD
Levomilnacipran—Anorexia—Prednisone—ankylosing spondylitis	0.000303	0.0024	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000298	0.00237	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000298	0.00237	CcSEcCtD
Levomilnacipran—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000296	0.00235	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000295	0.00234	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—ankylosing spondylitis	0.000291	0.00231	CcSEcCtD
Levomilnacipran—Urticaria—Dexamethasone—ankylosing spondylitis	0.00029	0.0023	CcSEcCtD
Levomilnacipran—Urticaria—Betamethasone—ankylosing spondylitis	0.00029	0.0023	CcSEcCtD
Levomilnacipran—Dizziness—Prednisolone—ankylosing spondylitis	0.000289	0.00229	CcSEcCtD
Levomilnacipran—Asthenia—Triamcinolone—ankylosing spondylitis	0.000288	0.00229	CcSEcCtD
Levomilnacipran—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000288	0.00229	CcSEcCtD
Levomilnacipran—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000288	0.00229	CcSEcCtD
Levomilnacipran—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000288	0.00229	CcSEcCtD
Levomilnacipran—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000288	0.00229	CcSEcCtD
Levomilnacipran—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000288	0.00228	CcSEcCtD
Levomilnacipran—Insomnia—Prednisone—ankylosing spondylitis	0.000287	0.00228	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisone—ankylosing spondylitis	0.000285	0.00226	CcSEcCtD
Levomilnacipran—Pruritus—Triamcinolone—ankylosing spondylitis	0.000284	0.00226	CcSEcCtD
Levomilnacipran—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000284	0.00225	CcSEcCtD
Levomilnacipran—Convulsion—Methotrexate—ankylosing spondylitis	0.000282	0.00224	CcSEcCtD
Levomilnacipran—Dyspepsia—Prednisone—ankylosing spondylitis	0.000279	0.00222	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—ankylosing spondylitis	0.000277	0.0022	CcSEcCtD
Levomilnacipran—Decreased appetite—Prednisone—ankylosing spondylitis	0.000276	0.00219	CcSEcCtD
Levomilnacipran—Rash—Prednisolone—ankylosing spondylitis	0.000275	0.00219	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisolone—ankylosing spondylitis	0.000275	0.00218	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000275	0.00218	CcSEcCtD
Levomilnacipran—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000274	0.00218	CcSEcCtD
Levomilnacipran—Fatigue—Prednisone—ankylosing spondylitis	0.000274	0.00217	CcSEcCtD
Levomilnacipran—Headache—Prednisolone—ankylosing spondylitis	0.000274	0.00217	CcSEcCtD
Levomilnacipran—Constipation—Prednisone—ankylosing spondylitis	0.000271	0.00215	CcSEcCtD
Levomilnacipran—Dizziness—Triamcinolone—ankylosing spondylitis	0.000266	0.00211	CcSEcCtD
Levomilnacipran—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000265	0.0021	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—ankylosing spondylitis	0.000264	0.00209	CcSEcCtD
Levomilnacipran—Asthenia—Betamethasone—ankylosing spondylitis	0.000262	0.00208	CcSEcCtD
Levomilnacipran—Asthenia—Dexamethasone—ankylosing spondylitis	0.000262	0.00208	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00026	0.00206	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.00026	0.00206	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.00026	0.00206	CcSEcCtD
Levomilnacipran—Nausea—Prednisolone—ankylosing spondylitis	0.00026	0.00206	CcSEcCtD
Levomilnacipran—Pruritus—Betamethasone—ankylosing spondylitis	0.000258	0.00205	CcSEcCtD
Levomilnacipran—Pruritus—Dexamethasone—ankylosing spondylitis	0.000258	0.00205	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—ankylosing spondylitis	0.000258	0.00205	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000257	0.00204	CcSEcCtD
Levomilnacipran—Vomiting—Triamcinolone—ankylosing spondylitis	0.000255	0.00203	CcSEcCtD
Levomilnacipran—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000255	0.00202	CcSEcCtD
Levomilnacipran—Rash—Triamcinolone—ankylosing spondylitis	0.000253	0.00201	CcSEcCtD
Levomilnacipran—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000253	0.00201	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—ankylosing spondylitis	0.000253	0.00201	CcSEcCtD
Levomilnacipran—Rash—Methylprednisolone—ankylosing spondylitis	0.000253	0.00201	CcSEcCtD
Levomilnacipran—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000253	0.002	CcSEcCtD
Levomilnacipran—Urticaria—Prednisone—ankylosing spondylitis	0.000252	0.002	CcSEcCtD
Levomilnacipran—Headache—Triamcinolone—ankylosing spondylitis	0.000252	0.002	CcSEcCtD
Levomilnacipran—Headache—Methylprednisolone—ankylosing spondylitis	0.000251	0.00199	CcSEcCtD
Levomilnacipran—Body temperature increased—Prednisone—ankylosing spondylitis	0.000251	0.00199	CcSEcCtD
Levomilnacipran—Abdominal pain—Prednisone—ankylosing spondylitis	0.000251	0.00199	CcSEcCtD
Levomilnacipran—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000249	0.00198	CcSEcCtD
Levomilnacipran—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000249	0.00198	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—ankylosing spondylitis	0.000248	0.00197	CcSEcCtD
Levomilnacipran—Dizziness—Dexamethasone—ankylosing spondylitis	0.000241	0.00191	CcSEcCtD
Levomilnacipran—Dizziness—Betamethasone—ankylosing spondylitis	0.000241	0.00191	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—ankylosing spondylitis	0.00024	0.0019	CcSEcCtD
Levomilnacipran—Nausea—Triamcinolone—ankylosing spondylitis	0.000239	0.00189	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000238	0.00189	CcSEcCtD
Levomilnacipran—Nausea—Methylprednisolone—ankylosing spondylitis	0.000238	0.00189	CcSEcCtD
Levomilnacipran—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000237	0.00188	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—ankylosing spondylitis	0.000236	0.00187	CcSEcCtD
Levomilnacipran—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000234	0.00186	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000234	0.00185	CcSEcCtD
Levomilnacipran—Vomiting—Betamethasone—ankylosing spondylitis	0.000232	0.00184	CcSEcCtD
Levomilnacipran—Vomiting—Dexamethasone—ankylosing spondylitis	0.000232	0.00184	CcSEcCtD
Levomilnacipran—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000231	0.00183	CcSEcCtD
Levomilnacipran—Rash—Dexamethasone—ankylosing spondylitis	0.00023	0.00182	CcSEcCtD
Levomilnacipran—Rash—Betamethasone—ankylosing spondylitis	0.00023	0.00182	CcSEcCtD
Levomilnacipran—Dermatitis—Betamethasone—ankylosing spondylitis	0.00023	0.00182	CcSEcCtD
Levomilnacipran—Dermatitis—Dexamethasone—ankylosing spondylitis	0.00023	0.00182	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000229	0.00182	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—ankylosing spondylitis	0.000229	0.00182	CcSEcCtD
Levomilnacipran—Headache—Betamethasone—ankylosing spondylitis	0.000228	0.00181	CcSEcCtD
Levomilnacipran—Headache—Dexamethasone—ankylosing spondylitis	0.000228	0.00181	CcSEcCtD
Levomilnacipran—Asthenia—Prednisone—ankylosing spondylitis	0.000228	0.00181	CcSEcCtD
Levomilnacipran—Pruritus—Prednisone—ankylosing spondylitis	0.000225	0.00178	CcSEcCtD
Levomilnacipran—Diarrhoea—Prednisone—ankylosing spondylitis	0.000217	0.00172	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000217	0.00172	CcSEcCtD
Levomilnacipran—Nausea—Dexamethasone—ankylosing spondylitis	0.000217	0.00172	CcSEcCtD
Levomilnacipran—Nausea—Betamethasone—ankylosing spondylitis	0.000217	0.00172	CcSEcCtD
Levomilnacipran—Urticaria—Methotrexate—ankylosing spondylitis	0.000211	0.00167	CcSEcCtD
Levomilnacipran—Dizziness—Prednisone—ankylosing spondylitis	0.00021	0.00167	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—ankylosing spondylitis	0.00021	0.00166	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—ankylosing spondylitis	0.00021	0.00166	CcSEcCtD
Levomilnacipran—Vomiting—Prednisone—ankylosing spondylitis	0.000202	0.0016	CcSEcCtD
Levomilnacipran—Rash—Prednisone—ankylosing spondylitis	0.0002	0.00159	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisone—ankylosing spondylitis	0.0002	0.00159	CcSEcCtD
Levomilnacipran—Headache—Prednisone—ankylosing spondylitis	0.000199	0.00158	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000195	0.00155	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—ankylosing spondylitis	0.00019	0.00151	CcSEcCtD
Levomilnacipran—Nausea—Prednisone—ankylosing spondylitis	0.000189	0.0015	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—ankylosing spondylitis	0.000188	0.00149	CcSEcCtD
Levomilnacipran—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000182	0.00144	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—ankylosing spondylitis	0.000175	0.00139	CcSEcCtD
Levomilnacipran—Vomiting—Methotrexate—ankylosing spondylitis	0.000169	0.00134	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—ankylosing spondylitis	0.000167	0.00133	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—ankylosing spondylitis	0.000167	0.00133	CcSEcCtD
Levomilnacipran—Headache—Methotrexate—ankylosing spondylitis	0.000166	0.00132	CcSEcCtD
Levomilnacipran—Nausea—Methotrexate—ankylosing spondylitis	0.000158	0.00125	CcSEcCtD
